VAERS Explorer
Back to explore

Report #2846574

Received Jun 19, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
PA
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS1UNK—

Symptoms (2)

FatiguePain in extremity

Symptom narrative

tiredness; arm soreness; This non-serious case was reported by a consumer via call center representative and described the occurrence of tiredness in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included herpes simplex type ii (About 20 years ago, the patient contacted genital herpes). Concomitant products included aciclovir sodium (Acyclovir) and valaciclovir hydrochloride (Valtrex). On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced tiredness (Verbatim: tiredness) and pain in arm (Verbatim: arm soreness). The outcome of the tiredness and pain in arm were unknown. It was unknown if the reporter considered the tiredness and pain in arm to be related to Shingrix. It was unknown if the company considered the tiredness and pain in arm to be related to Shingrix. Linked case(s) involving the same patient: US2025AMR071843, US2025AMR076294 Additional Information: GSK Receipt Date: 09-JUN-2025 The reporter was the patient. The patient also lives part of the year in another country. The patient received the first of Shingrix in 2018 The only side effects experienced by the patient from any dose of Shingrix were arm soreness and tiredness. About 20 years ago, the patient contacted genital herpes (Herpes Simplex 2). The patient had taken Valtrex, then went to Acyclovir for suppressive therapy. For tolerance to second dose, refer case US2025AMR076294 For tolerance to third dose, refer case US2025AMR071843; Sender's Comments: US-GSK-US2025AMR071843:Same patient, 3rd dose US-GSK-US2025AMR076294:Same patient, 2nd dose

Current illness

Herpes simplex type II (About 20 years ago, the patient contacted genital herpes)

Other medications

ACYCLOVIR; VALTREX